Gemtuzumab Ozogamicin biological API (CAS No. 220578-59-6) is a targeted antineoplastic antibody-drug conjugate associated with acute myeloid leukemia, hematologic oncology, and advanced biologic pharmaceutical development.
Gemtuzumab Ozogamicin is a CD33-directed antibody-drug conjugate composed of a humanized IgG4 kappa monoclonal antibody, known as hP67.6, covalently linked to a cytotoxic N-acetyl-gamma-calicheamicin derivative through a chemical linker.
The antibody component selectively recognizes human CD33 antigen, a cell-surface antigen expressed on myeloid leukemic blast cells.
Following binding to CD33-expressing cells, the Gemtuzumab Ozogamicin-CD33 complex undergoes cellular internalization.
Intracellular processing and hydrolytic cleavage of the linker release the cytotoxic calicheamicin-derived payload.
The activated calicheamicin derivative interacts with DNA and induces double-strand DNA breaks. This DNA damage leads to cell-cycle arrest and apoptotic cell death.
Gemtuzumab Ozogamicin is associated with targeted treatment strategies for CD33-positive acute myeloid leukemia and represents an important antibody-drug conjugate platform in hematologic oncology.
Pharmaceutical and biotechnology companies evaluating Gemtuzumab Ozogamicin biological active substance commonly focus on antibody identity, ADC purity, protein concentration, CD33-binding activity, biological potency, drug-to-antibody ratio, conjugation profile, free calicheamicin-related payload, aggregates, charge variants, glycosylation characteristics, linker stability, host cell proteins, residual host cell DNA, endotoxin, bioburden, and batch-to-batch consistency.
Because Gemtuzumab Ozogamicin is a complex antibody-drug conjugate, conventional small-molecule API parameters such as melting point, specific rotation, residue on ignition, and simple HPLC assay are generally not sufficient to characterize the active substance.
Product-specific orthogonal analytical methods are required to evaluate the monoclonal antibody, linker, cytotoxic payload, conjugation characteristics, and overall ADC biological activity.
Swapnroop Drugs and Pharmaceuticals supports Gemtuzumab Ozogamicin biological active material sourcing and supply coordination for qualified pharmaceutical research, antibody-drug conjugate development, analytical characterization, hematologic oncology research, and biologic pharmaceutical development requirements.
Get Bulk Quote via WhatsApp